Skip to Content

  • Search

View Additional Section Content

A multi-center, randomized, blinded, parallel-group study of the reduction of signs and symptoms during monotherapy treatment with Tocilizumab 8mg/kg intravenously versus Adalimumab 40mg subcutaneously in patients with rheumatoid arthritis

Principal Investigator(s)
Dennis A. Jerdan, M.D.
C. Michael Franklin, M.D. (Sub-Investigator)
Charles H. Pritchard, M.D. (Sub-Investigator)
Mark Lopatin, M.D. (Sub-Investigator)
David J. Chesner, D.O. (Sub-Investigator)
Elana R. Eisner, M.D. (Sub-Investigator)
Marguerite L. McGarvey, M.D. (Sub-Investigator)

Clinical Trial Categories

  • Arthritis
Sue Falbo at 215-657-9977


  • Rheumatic Disease Associates, Ltd.

Find a Physician
Search Our Directory


Schedule a Test
Request an Appointment


Clinical Trials Details